KEY TAKEAWAY: “We still believe that amyloid beta hypothesis is potentially the right approach for the treatment of Alzheimer’s disease,” an Eisai spokesman told Reuters. What made Wall Street and everyone else, Eli Lilly, AstraZeneca, Merck, and Roche — have reported out decisive late-stage failures over the last year that all point to one conclusion: Targeting amyloid-beta alone in symptomatic patients may hit your biomarkers on effect, but it doesn’t delay the ruthless march of the disease.Continue reading
- Eisai and Biogen posted promising data for BAN2401 that lifted its stock and had the pharma trade publications talking breakthrough.
- But there is a lot of controversy swirling around the study.
- It seems that Biogen may have moved the goal posts to gain more favorable data endpoints.
- It’s not about patients, it’s about the stock price and getting investors on board.
KEY TAKEAWAY: When a CEO decides to take the money and leave a company facing challenges you have to wonder why in the hell he was eve named CEO? Continue reading
KEY TAKEAWAY: Spending $40 million on a DTC campaign to increase awareness of a drug that people are demolishing on social media is a waste of money. Surely DTC marketers can do better than this. Continue reading